Background: Hormone receptor (HR)-positive HER2-negative breast cancer (BC) rates and associated mortality have been increasing among Japanese women. It is unclear whether the prognosis of these patients has improved. Methods: We retrospectively analyzed 1806 Japanese women with operable invasive HR-positive HER2-negative BC, who underwent complete resection at the National Cancer Center Hospital East between July 1992 and December 2010. We investigated whether overall survival (OS) and recurrencefree survival (RFS) had improved by comparing the 4-year periods 1992-96, 1997-2001, 2002-06, and 2007-10. The prognostic factors were evaluated using uni-and multivariate analyses. Results: The number of ER-and PgR-positive cancers had increased over the years (P < 0.001). Tumor sizes and numbers of involved lymph nodes both gradually decreased (P < 0.001 for both). OS and RFS of all patients significantly improved in each of the periods analyzed: 5-year OS was 92.6%, 94.8%, 95.4% and 97.6% (P < 0.001, Log-rank), and 5-year RFS was 82.1%, 82.8%, 88.6% and 94.5% (P < 0.001) in 1992-96, 1997-2001, 2002-06 and 2007-10, respectively. In multivariate analysis, the history of adjuvant AI and that of TAM had positive-correlation with RFS. Conclusions: The prognosis for HR-positive HER2-negative BC patients after surgical therapy has improved, resulting in longer OS and RFS across the study periods. These changes could be associated with early detection of tumor and history of hormone therapy.
Introduction
Breast cancer (BC) rates have been increasing and it is now the most common cancer and the third leading cause of cancer death among Japanese women, with 113.0 cases/100 000 and 19.4 deaths/ 100 000 in 2012 (1, 2) . Since it is a heterogeneous disease, treatments for BC have been developed based on the biological features of each subtype, identified by the presence or absence of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 (3) (4) (5) (6) , and utilizing endocrine therapies, chemotherapies and targeted biological agents.
More effective therapeutic approaches have been approved through long-term experience in the adjuvant setting. For patients with the HER2-enriched subtype, the advent of targeted therapies, such as the addition of trastuzumab to chemotherapy has led to improved disease-free survival (DFS) and overall survival (OS) compared with chemotherapy alone (7) (8) (9) . For HER2-negative patients, who are divided into two subtypes based on hormone receptor (HR) positivity, pivotal randomized Phase III clinical trials demonstrated that the use of adjuvant therapies, such as AI including anastrozole (10) , letrozole (11) and exemestane (12) and the addition of paclitaxel to an anthracycline-based regimen (13, 14) , resulted in improved DFS (or recurrence-free survival (RFS)) and thus, indirectly OS (3, (13) (14) (15) (16) .
Some previous studies also had investigated progress in reducing BC mortality for all subtypes including both HER2-positive and triple negative disease (17, 18) , for HR-positive BC which was either HER2-positive or HER2-negative (19) , or for all subtypes in the adjuvant and recurrent setting (20) . However, the real trend in survival time for early HR-positive and HER2-negative BC has not been clearly established. Thus, we analyzed whether OS of this population at a single center in Japan improved over the past two decades. And if we could predict their survival, what factors were associated with recurrence after surgery.
Patients and methods

Patients
A total of 2965 women with newly diagnosed invasive BC underwent radical resection for early disease at the National Cancer Center Hospital East in Japan between July 1992 and December 2010. Among them, we analyzed patients with HR-positive and HER2-negative status. Exclusion criteria were male sex, Stage IV disease, or having a history of other cancers.
All data regarding patient characteristics and treatment outcomes were collected retrospectively from medical records. Information on the following parameters was available for all patients: age; menopausal status at the time of surgery; clinical stage; treatment history including operation type, radiation therapy, hormonal therapy and chemotherapy; clinicopathological findings; and survival status. For patients who had received neoadjuvant therapy, classification of tumor size and nodal status was based on clinical information. For patients who had not, it was based on pathological information where available, and on clinical information where not. Patients were divided into groups, according to the time when they began treatment, as follows: 1992-96, 1997-2001, 2002-06 and 2007-10, by equally dividing up the entire time period. In addition, 1997 was chosen as the cutoff dividing year for our study because two taxanes, docetaxel and paclitaxel, were approved for use in Japan in that year.
We investigated whether OS and RFS has improved over the past few years. OS was defined as the time from the date of operation to death from any cause. RFS was defined as the time from the operation day to the first of one of the following events: recurrence at local, regional, or distant sites; or a new invasive cancer in the contralateral breast. Patient follow-up was censored at 31 July 2015. The occurrence of a second type of cancer or death without breast cancer recurrence was not included as an event in this RFS; data for patients who died from any cause without recurrence were censored at the date of death. Survival from the time of recurrence was defined as the time from the day of recurrence diagnosed by a physician to death from breast cancer.
This study was carried out in accordance with the Declaration of Helsinki and Japanese ethical guidelines for epidemiological research. We obtained institutional review board waivers to conduct this study.
Immunohistochemical evaluation of ER, PgR and HER2 status
Tumors were tested for estrogen receptor (ER) and progesterone recep- (24, 25) . Patients with a prior-history of trastuzumab therapy without histologically-proven HER2-positive status, were also defined as a clinically HER2-enriched subtype.
Statistical analysis
Demographic factors were tabulated and any imbalance among the study periods was examined by one-way analysis of variance, Fisher's exact test and the chi-square test for continuous, two-level categorical and multi-level categorical variables, respectively.
Kaplan-Meier curves were depicted according to the study periods for OS, RFS and survival from the time of recurrence diagnosis, and differences among the study periods were explored by log-rank test. To compare the distribution of recurrence time among study periods, we defined the four recurrence periods of 0-2, 2-5, 5-10 and >10 years, a piecewise exponential model was fitted and the recurrence-period-bystudy-period interaction was tested. Univariate analysis and a multivariate Cox regression were conducted to investigate the prognostic factors for RFS, where the variables for the univariate analysis were selected according to our clinical considerations. Multivariate analysis was performed with all variables that were statistically significant in the univariate analyses and the step-down variable selection was conducted.
Results
Patient characteristics
Among the 2965 newly diagnosed women who underwent radical resection, some patients were excluded for the following reasons; 865 patients who were both ER and PgR negative; 158 patients with a histologically HER2-enriched subtype including 107 patients with both ER-and PgR-positive tumors, 40 patients with ER-positive The number of patients grew with each study period and the median age of all patients increased significantly over the four study periods (P < 0.001). This tendency was also seen among postmenopausal patients, although the median age of premenopausal women remained the same at 46 years old (Supplemental Table S1a and S1b). In menopausal status, the proportion of postmenopausal women gradually increased from 50% to 65% (P < 0.001). Analysis of histological subtype revealed that the proportion of both ER-and PgR-positive cancers had increased over the years (P < 0.001), especially in premenopausal patients (data not shown). Tumor sizes and numbers of involved lymph nodes both gradually decreased (P < 0.001 for both). The number of patients receiving neoadjuvant or adjuvant chemotherapies was less than half during each study period, although the number of postmenopausal women receiving neoadjuvant or adjuvant chemotherapies was lower than that of premenopausal women. However the number of patients receiving adjuvant hormonal therapies significantly increased, regardless of menopausal status (Table 1 and  supplemental Table S1a and S1b). As 60% or more of postmenopausal patients had been treated with adjuvant AI therapies, the number of patients treated with tamoxifen (TAM) alone decreased. The data of patient characteristics and tumor features are shown in Table 1 . (Fig. 1a and b) , showing a significant improvement in OS and RFS over time.
Survival outcomes of RFS and OS
The recurrence rate in any recurrence period seemed to decrease over time. Regarding the timing of recurrence, the number of patients who relapsed within 2 years after surgery decreased during each separate time period (P < 0.004, as shown in Table 2 ). In contrast, the women who relapsed after 2 years but within 5 years increased over time.
OS and RFS in premenopausal women diagnosed since 1997 were both significantly longer than in those diagnosed between 1992 and 1996 (log-rank test: P = 0.001). In postmenopausal women, RFS also gradually increased (log-rank test: P < 0.001), although there was no significant difference between 1992-96 and 1997-2001 (OS not shown, RFS shown in Fig. S1a and S1b).
Prognostic factors for recurrence
Several prognostic parameters were analyzed for association with survival. In univariate analyses, hormonal status, tumor size, numbers of involved lymph nodes, histological grade and having history of postoperative radiation therapy, chemotherapy and hormone therapy were identified as being significantly associated with survival (Table 3) . In multivariate analysis, tumor size, involved nodal status, histological grades and the history of hormone therapy had correlation with RFS.
Survival from time of recurrence
There was no significant difference in post-recurrence OS between the four time periods (Fig. 2) .
Discussion
We investigated disease outcomes in women who underwent radical resection for HR-positive and HER2-negative invasive BC, over the last two decades. Our study is a high-volume retrospective study with long-term follow-up and all corresponding patients are covered. The results show that OS and RFS significantly improved over time, which was independent of menopausal status.
Focusing particularly on premenopausal status, our results show that OS and RFS were both significantly improved since 1997-2001, even though the median age and the frequency of adjuvant therapies were both similar in each period. This may be attributed to the following reasons. First, the tumors may have more favorable profiles as indicated by their smaller size and the smaller number of involved lymph nodes, reflecting the findings of previous statistical analyses showing that death rates for female breast cancer are down 35% from peak rates as a result of improvements in early detection (4, 26, 27) . Second, it has become more common for BC patients to receive radiotherapy and hormonal therapy. Adjuvant chemotherapies using an anthracycline and taxane regimen rather than CMF (6,28) may be another reason for improved OS.
Focusing on postmenopausal status, we found that the median age and the number of newly diagnosed patients both increased, but nevertheless RFS significantly improved from 83% in 1992-96 to 89% in 2002-06 and 98% in 2007-10. It is considered that large RCTs (10, 11, (29) (30) (31) are not sufficient in themselves to account for improvements in OS. This may, therefore, be attributed to early detection as indirectly indicated by the decreasing proportion of patients receiving adjuvant chemotherapies.
Our statistical analysis did not show improved survival from the time of recurrence, but this may be due to our small sample size, the patients' complicated backgrounds and the variety of treatments after relapse. This was not in agreement with the results of a previous report (20, 32, 33) which showed that the prognosis for patients with recurrent BC also improved over time.
Several limitations of this study should be acknowledged. Firstly, patients were from a single institution, however, the physicians followed similar follow-up procedures, minimizing ascertainment bias. Secondly, one-fifth of all patients in this study were treated with neoadjuvant chemotherapy (NAC). However, patients with HR-positive tumors usually have low rates of pathological complete response (pCR) and maintain a good long-term outcome even in the presence of residual disease (34) . In addition, neoadjuvant therapy was apparently equivalent to adjuvant therapy in terms of survival and overall disease progression (35) . Therefore, it had little impact on their prognosis. Thirdly, the patients received various different adjuvant therapies so that we could not examine the dosing period or dose per day of various medications, or medicine-taking compliance including luteinizing hormone-releasing hormone (LHRH) analogs. The patients received TAM & AI contained those who discontinue hormone therapies by adverse event. It may influence the result of negative predictive factors for RFS. Fourthly, there was insufficient information about patients' background such as complications and any medication, which might influence their prognosis. Finally, it is difficult to strictly compare the prognosis of ER-positive patients between each period because both the cutoff level of ER-positively and the test procedures for ER immunostaining had not been standardized at the time.
Conclusions
In summary, our study demonstrates progress in treating BC revealed by the longer OS and RFS after radical surgery in patients with HR-positive HER2-negative breast cancer over recent decades.
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